Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Hereditary Cancer in Clinical Practice
Published in: Hereditary Cancer in Clinical Practice 2/2007

Open Access 01-12-2007 | Research

Some Molecular and Clinical Aspects of Genetic Predisposition to Malignant Melanoma and Tumours of Various Site of Origin

Author: Tadeusz Dębniak

Published in: Hereditary Cancer in Clinical Practice | Issue 2/2007

Login to get access

Abstract

Based on epidemiological data we can assume that at least some malignant melanoma (MM) and breast cancer cases can be caused by the same genetic factors. CDKN2A, which encodes the p16 protein, a cyclin-dependent kinase inhibitor suppressing cell proliferation, is regarded as a major melanoma susceptibility gene and the literature has also implicated this gene in predisposition to breast cancer. Genes also known to predispose to MM include XPD and MC1R. We studied CDKN2A/ARF, XPD and MC1R for their associations with melanoma and breast cancer risk in Polish patients and controls. We found that CDKN2A and ARF do not contribute significantly to either familial melanoma or malignant melanoma within the context of a cancer familial aggregation of disease with breast cancer. However, the common variant of the CDKN2A gene A148T, previously regarded as non-pathogenic, may predispose to malignant melanoma, early-onset breast cancer and lung cancer. Compound carriers of common XPD variants may be at slightly increased risk of breast cancer or late–onset malignant melanoma. Common recurrent variants of the MC1R gene (V60L, R151C, R163Q and R160W) may predispose to malignant melanoma. In general, the establishment of surveillance protocols proposed as an option for carriers of common alterations in CDKN2A, XPD or MC1R variants requires additional studies. It is possible that missense variants of genes for which truncating mutations are clearly pathogenic may also be deleterious, but with reduced penetrance. This may be overlooked unless large numbers of patients and controls are studied. A registry that includes 2000 consecutive breast cancer cases, 3500 early onset breast cancer patients, 500 unselected malignant melanoma and over 700 colorectal cancer patients has been established in the International Hereditary Cancer Centre and can contribute to these types of large association studies.
Literature
1.
The Breast Cancer Linkage Consortium: Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999, 91: 1310–1316.CrossRef
2.
Weston B, Grufferman S, Kostyu D, Burton CS, Grant J: Familial aggregation of melanoma, basal cell carcinoma, and gastric adenocarcinoma. Cancer 1986, 57: 2230–2234.CrossRefPubMed
3.
Hemminki K, Dong C: Subsequent cancers after in situ and invasive squamous cell carcinoma of the skin. Arch Dermatol 2000, 136: 647–651.CrossRefPubMed
4.
Azizi E, Friedman J, Pavlotsky F, Iscovich J, Bornstein A, Shafir R, Trau H, Brenner H, Nass D: Familial cutaneous malignant melanoma and tumors of the nervous system. A hereditary cancer syndrome. Cancer 1995, 76: 1571–1578.CrossRefPubMed
5.
Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, Benard J, Bressac-de Paillerets B: Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group Hum Mol Genet 1998, 7: 209–216.
6.
Fitzgerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, O'Neill E, Koh J, Finkelstein DM, Isselbacher KJ, Sober AJ, Haber DA: Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA 1996, 93: 8541–8545.PubMedCentralCrossRefPubMed
7.
Platz A, Hansson J, Ringborg U: Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study. Int J Cancer 1998, 25: 13–15.CrossRef
8.
Platz A, Hansson J, Mansson-Brahme E, Lagerlof B, Linder S, Lundqvist E, Sevigny P, Inganas M, Ringborg U: Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst 1997, 89: 697–702.CrossRefPubMed
9.
Lamperska K, Karezewska A, Kwiatkowska E, Mackiewicz A: Analysis of mutations in the p16/CDKN2A gene in sporadic and familial melanoma in the Polish population. Acta Biochim Pol 2002, 49: 369–376.PubMed
10.
Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, Sibley K, Whitaker L, Knowles M, Bishop JN, Bishop DT: A germline deletion of p14 (ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 2001, 10: 55–62.CrossRefPubMed
11.
Hewitt C, Lee Wu C, Evans G, Howell A, Elles RG, Jordan R, Sloan P, Read AP, Thakker N: Germline mutation of ARF in a melanoma kindred. Hum Mol Genet 2002, 11: 1273–1279.CrossRefPubMed
12.
Bahuau M, Vidaud D, Jenkins RB, Bieche I, Kimmel DW, Assouline B, Smith JS, Alderete B, Cayuela JM, Harpey JP, Caille B, Vidaud M: Germline deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res 1998, 58: 2298–2303.PubMed
13.
Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, Kluijt I, Dommering C, Verhoef S, Schouten JP, van't Veer LJ, Pals G: Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 2003, 63: 1449–1453.PubMed
14.
Nakagawa H, Hampel H, de la Chapelle A: Identification and characterization of genomic rearrangements of MSH2 and MLH1 in Lynch syndrome (HNPCC) by novel techniques. Hum Mutat 2003, 22: 258.CrossRefPubMed
15.
Lahiri DK, Schnabel B: DNA isolation by rapid method from human blood samples: effects of MgCl2, EDTA, storage time, and temperature on DNA yield and quality. Biochem Genet 1993, 31: 321–328.CrossRefPubMed
16.
Kumar R, Smeds J, Berggren P, Straume O, Rozell BL, Akslen LA, Hemminki K: A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare. Int J Cancer 2001, 95: 388–393.CrossRefPubMed
17.
Straume O, Smeds J, Kumar R, Hemminki K, Akslen LA: Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol 2002, 161: 229–237.PubMedCentralCrossRefPubMed
18.
Aitken J, Welch J, Duffy D, Milligan A, Green A, Martin N, Hayward N: CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 1999, 91: 446–452.CrossRefPubMed
19.
Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D, Dracopoli NC: Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 1995, 10: 114–116.CrossRefPubMed
20.
Lilischkis R, Sarcevic B, Kennedy C, Warlters A, Sutherland RL: Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity. Int J Cancer 1996, 66: 249–254.CrossRefPubMed
21.
Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366: 704–707.CrossRefPubMed
22.
Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, Westerdahl J, Olsson H, Ingvar C: High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000, 92: 1260–1266.CrossRefPubMed
23.
Whelan AJ, Bartsch D, Goodfellow PJ: Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Eng J Med 1995, 333: 975–977.CrossRef
24.
Van Zee KJ, Calvano JE, Bisogna M: Hypomethylation and increased gene expression of p16INK4a in primary and metastatic breast carcinoma as compared to normal breast tissue. Oncogene 1998, 16: 2723–2727.CrossRefPubMed
25.
Ghiorzo P, Ciotti P, Mantelli M, Heouaine A, Queirolo P, Rainero ML, Ferrari C, Santi PL, De Marchi R, Farris A, Ajmar F, Bruzzi P, Bianchi-Scarra G: Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer 1999, 83: 441–448.CrossRefPubMed
26.
Nielsen NH, Roos G, Emdin SO, Landberg G: Methylation of the p16 (Ink4a) tumor suppressor gene 5"-CpG island in breast cancer. Cancer Lett 2001, 163: 59–69.CrossRefPubMed
27.
Gorgoulis VG, Koutroumbi EN, Kotsinas A, Zacharatos P, Markopoulos C, Giannikos L, Kyriakou V, Voulgaris Z, Gogas I, Kittas C: Alterations of p16-pRb pathway and chromosome locus 9p21–22 in sporadic invasive breast carcinomas. Mol Med 1998, 4: 807–822.PubMedCentralPubMed
28.
Schneider-Stock R, Giers A, Motsch C, Boltze C, Evert M, Freigang B, Roessner A: Hereditary p16-Leiden mutation in a patient with multiple head and neck tumors. Am J Hum Genet 2003, 72: 216–218.PubMedCentralCrossRefPubMed
29.
Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, Herman JG: Aberrant methylation of p16 (INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998, 95: 11891–11896.PubMedCentralCrossRefPubMed
30.
Smigiel R, Sasiadek M, Krecicki T, Ramsey D, Jagielski J, Blin N: Inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene in squamous cell carcinoma of the larynx. Mol Carcinog 2004, 39: 147–154.CrossRefPubMed
31.
32.
Cleaver JE, Thompson LH, Richardson AS, States JC: A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. Hum Mutat 1999, 14: 9–22.CrossRefPubMed
33.
Berneburg M, Lehmann AR: Xeroderma pigmentosum and related disorders: defects in DNA repair and transcription. Adv Genet 2001, 43: 71–102.CrossRefPubMed
34.
Broughton BC, Steingrimsdottir H, Weber CA, Lehmann AR: Mutations in the xeroderma pigmentosum group D DNA repair/transcription gene in patients with trichothiodystrophy. Nat Genet 1994, 7: 189–194.CrossRefPubMed
35.
Tomescu D, Kavanagh G, Ha T, Campbell H, Melton DW: Nucleotide excision repair gene XPD polymorphisms and genetic predisposition to melanoma. Carcinogenesis 2001, 22: 403–408.CrossRefPubMed
36.
Winsey SL, Haldar NA, Marsh HP, Bunce M, Marshall SE, Harris AL, Wojnarowska F, Welsh KI: A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res 2000, 60: 5612–5616.PubMed
37.
Han J, Colditz GA, Liu JS, Hunter DJ: Genetic variation in XPD, sun exposure, and risk of skin cancer. Cancer Epidemiol Biomarkers Prev 2005, 14: 1539–1544.CrossRefPubMed
38.
Baccarelli A, Calista D, Minghetti P, Marinelli B, Albetti B, Tseng T, Hedayati M, Grossman L, Landi G, Struewing JP, Landi MT: XPD gene polymorphism and host characteristics in the association with cutaneous malignant melanoma risk. Br J Cancer 2004, 90: 497–502.PubMedCentralCrossRefPubMed
39.
Justenhoven C, Hamann U, Pesch B, Harth V, Rabstein S, Baisch C, Vollmert C, Illig T, Ko YD, Bruning T, Brauch H: ERCC2 genotypes and a corresponding haplotype are linked with breast cancer risk in a German population. Cancer Epidemiol Biomarkers Prev 2004, 13: 2059–2064.PubMed
40.
Zhang L, Zhang Z, Yan W: Single nucleotide polymorphisms for DNA repair genes in breast cancer patients. Clin Chim Acta 2005, 359: 150–155.CrossRefPubMed
41.
Forsti A, Angelini S, Festa F, Sanyal S, Zhang Z, Grzybowska E, Pamula J, Pekala W, Zientek H, Hemminki K, Kumar R: Single nucleotide polymorphisms in breast cancer. Oncol Rep 2004, 11: 917–922.PubMed
42.
Hashemi J, Platz A, Ueno T, Stierner U, Ringborg U, Hansson J: CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Cancer Res 2000, 60: 6864–6867.PubMed
43.
Valverde P, Healy E, Jackson I, Rees JL, Thody AJ: Variants of the melanocyte stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995, 11: 328–330.CrossRefPubMed
44.
Palmer JS, Duffy DL, Box NF, Aitken JF, O'Gorman LE, Green AC, Hayward NK, Martin NG, Sturm RA: Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000, 66: 176–186.PubMedCentralCrossRefPubMed
45.
Box NF, Wyeth JR, O'Gorman LE, Martin NG, Sturm RA: Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair. Hum Mol Genet 1997, 6: 1891–1897.CrossRefPubMed
46.
Box NF, Duffy DL, Chen W, Stark M, Martin NG, Sturm RA, Hayward NK: MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001, 69: 765–773.PubMedCentralCrossRefPubMed
47.
Chaudru V, Laud K, Avril MF, Miniere A, Chompret A, Bressac-de Paillerets B, Demenais F: Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees. Cancer Epidemiol Biomarkers Prev 2005, 14: 2384–2390.CrossRefPubMed
48.
Kennedy C, ter Huurne J, Berkhout M, Gruis N, Bastiaens M, Bergman W, Willemze R, Bavinck JN: Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001, 117: 294–300.CrossRefPubMed
49.
Valverde P, Healy E, Sikkink S, Haldane F, Thody AJ, Carothers A, Jackson IJ, Rees JL: The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996, 5: 1663–1666.CrossRefPubMed
50.
Matichard E, Verpillat P, Meziani R, Gerard B, Descamps V, Legroux E, Burnouf M, Bertrand G, Bouscarat F, Archimbaud A, Picard C, Ollivaud L, Basset-Seguin N, Kerob D, Lanternier G, Lebbe C, Crickx B, Grandchamp B, Soufir N: Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure. J Med Genet 2004, 41: e13.PubMedCentralCrossRefPubMed
51.
Landi MT, Kanetsky PA, Tsang S, Gold B, Munroe D, Rebbeck T, Swoyer J, Ter-Minassian M, Hedayati M, Grossman L, Goldstein AM, Calista D, Pfeiffer RM: MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst 2005, 97: 998–1007.CrossRefPubMed
52.
Stratigos AJ, Dimisianos G, Nikolaou V, Poulou M, Sypsa V, Stefanaki I, Papadopoulos O, Polydorou D, Plaka M, Christofidou E, Gogas H, Tsoutsos D, Kastana O, Antoniou C, Hatzakis A, Kanavakis E, Katsambas AD: Melanocortin receptor-1 gene polymorphisms and the risk of cutaneous melanoma in a low-risk southern European population. J Invest Dermatol 2006, 126: 1842–1849.CrossRefPubMed
53.
Fargnoli MC, Altobelli E, Keller G, Chimenti S, Hofler H, Peris K: Contribution of melanocortin-1 receptor gene variants to sporadic cutaneous melanoma risk in a population in central Italy: a case-control study. Melanoma Res 2006, 16: 175–182.CrossRefPubMed
54.
Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Mitra N, Busam K, From L, Berwick M: Genes Environment and Melanoma Study Group. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 2005, 97: 1507–1515.CrossRefPubMed
Metadata
Title
Some Molecular and Clinical Aspects of Genetic Predisposition to Malignant Melanoma and Tumours of Various Site of Origin
Author
Tadeusz Dębniak
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Hereditary Cancer in Clinical Practice / Issue 2/2007
Electronic ISSN: 1897-4287
DOI
https://doi.org/10.1186/1897-4287-5-2-97

Other articles of this Issue 2/2007

Hereditary Cancer in Clinical Practice 2/2007 Go to the issue

Research

No Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1 Mutation Carriers

Research

Gene Expression Profiling in Familial Adenomatous Polyposis Adenomas and Desmoid Disease

Research

Colorectal Cancer in the Family: Psychosocial Distress and Social Issues in the Years Following Genetic Counselling

Case report

Familial Multiple Myeloma: Report on Two Families and Discussion of Screening Options
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits